Trial status
RECRUITMENT
The first patient was enrolled in October 2020, but patient recruitment was significantly slower than expected. So far 11 patients (13% of the planned sample size) are included in the study. Previously the anticipated number of patients was assumed to be enrolled within approximately 2 years. In the meantime, this turned out not to be feasible without an extension of the recruitment period. As gilteritinib is used increasingly in Germany, we finally decided to close the study prematurely.
